Seminoma of the testis: is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes?
OBJECTIVE
To evaluate the influence of different shielding conditions and field geometry on the scatter dose to the remaining testicle during postoperative radiotherapy (RT) in seminoma.


METHODS
Testicular dose measurements were made with LiF thermoluminescent dosimeters (TLD) in 29 patients with stage I and IIA seminoma. The target volume consisted of para-aortic (PA) and para-aortic and homolateral iliac (PAI) lymph nodes in 14 and 15 patients, respectively. All patients had a scrotal shield as well as an additional block extending 7 cm inferiorly from the caudal field edge to shield the testicle from external scatter and collimator leakage. Doses with and without testicular blocks were measured for all patients. In seven patients treated exclusively to the PA region the gonadal dose was assessed according to four different shielding conditions: without any protection, with a gonadal shield alone, with the addition of an inferior field border block to the gonadal shield, and with the field border block alone.


RESULTS
For patients treated with PAI fields the mean testicular doses per fraction were 3.89 cGy (S.D. +/- 1.44) and 1.48 cGy (S.D. +/- 0.51) without and with gonadal shielding, respectively (P-value < 0.001); the corresponding values for PA fields were 1.86 cGy (S.D. +/- 0.86) and 0.65 cGy (S.D. +/- 0.35). For the patients treated to the PA region and assessed according to the four different shielding conditions, the additional external block to the testicular shield did not reduce significantly the measured dose on the testis.


CONCLUSIONS
These results suggest a benefit of gonadal shielding even in seminoma patients undergoing radiotherapy limited to the para-aortic region.
Radiation Oncology Division, University Hospital of Geneva, Switzerland.
S
S
Bieri
M
M
Rouzaud
R
R
Miralbell
D000328:Adult; D006801:Humans; D008198:Lymph Nodes / Q000528:radiation effects*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011835:Radiation Protection / Q000295:instrumentation; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal / Q000379:methods; D012542:Scattering, Radiation; D012611:Scrotum / Q000528:radiation effects; D018239:Seminoma / Q000532:radiotherapy* / Q000601:surgery; D013736:Testicular Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D013737:Testis / Q000528:radiation effects; D013819:Thermoluminescent Dosimetry / Q000295:instrumentation